Bank of Montreal Can Sells 146,305 Shares of Smith & Nephew SNATS, Inc. $SNN

Bank of Montreal Can cut its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,283,524 shares of the medical equipment provider’s stock after selling 146,305 shares during the period. Bank of Montreal Can owned 0.77% of Smith & Nephew SNATS worth $119,159,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SNN. JPMorgan Chase & Co. boosted its holdings in Smith & Nephew SNATS by 6,663.4% in the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after acquiring an additional 1,192,755 shares in the last quarter. ABC Arbitrage SA grew its position in Smith & Nephew SNATS by 1,063.4% in the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock valued at $27,525,000 after purchasing an additional 821,393 shares during the period. Todd Asset Management LLC acquired a new stake in Smith & Nephew SNATS in the 3rd quarter valued at $26,319,000. Goldman Sachs Group Inc. increased its stake in Smith & Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Smith & Nephew SNATS by 365.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock valued at $19,742,000 after purchasing an additional 505,934 shares in the last quarter. 25.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on SNN shares. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Finally, Canaccord Genuity Group lifted their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Smith & Nephew SNATS currently has an average rating of “Hold” and an average price target of $36.25.

Smith & Nephew SNATS Trading Up 0.8%

NYSE SNN opened at $33.34 on Thursday. Smith & Nephew SNATS, Inc. has a 1 year low of $23.91 and a 1 year high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. The company has a fifty day moving average price of $34.46 and a 200-day moving average price of $34.84.

Smith & Nephew SNATS Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a dividend yield of 281.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.